C
Caroline Onions
Researcher at University of Nottingham
Publications - 2
Citations - 612
Caroline Onions is an academic researcher from University of Nottingham. The author has contributed to research in topics: Donepezil & Randomized controlled trial. The author has an hindex of 2, co-authored 2 publications receiving 573 citations.
Papers
More filters
Journal ArticleDOI
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Robert Howard,Rupert McShane,James Lindesay,Craig W. Ritchie,Ashley Baldwin,Robert Barber,Alistair Burns,Tom Dening,David Findlay,Clive Holmes,Alan Hughes,Robin Jacoby,Robert G. Jones,Roy W. Jones,Ian G. McKeith,Ajay Macharouthu,John T. O'Brien,Peter Passmore,Bart Sheehan,Edmund Juszczak,Cornelius Katona,Robert Kerrin Hills,Martin Knapp,Clive Ballard,Richard G. Brown,Sube Banerjee,Caroline Onions,Mary Griffin,Jessica Adams,Richard Gray,Tony Johnson,Peter Bentham,Patrick P. J. Phillips +32 more
TL;DR: In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months.
Journal ArticleDOI
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
Robert G. Jones,Bart Sheehan,Patrick P. J. Phillips,Ed Juszczak,Jessica Adams,Ashley Baldwin,Clive Ballard,Subrata Banerjee,Bob Barber,Peter Bentham,Richard G. Brown,Alistair Burns,Tom Dening,David Findlay,Richard Gray,Mary Griffin,Clive Holmes,Alan Hughes,Robin Jacoby,Tony Johnson,Roy W. Jones,Martin Knapp,James Lindesay,Ian G. McKeith,Rupert McShane,Ajay Macharouthu,John T. O'Brien,Caroline Onions,Peter Passmore,James Raftery,Craig W. Ritchie,Robert Howard +31 more
TL;DR: The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil, and to provide clear evidence on the best treatment strategies for those managing patients at a particularly important clinical transition point.